Hoey Investments’s Denali Therapeutics DNLI Stock Holding History

Hoey Investments’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100	Closed	-$3K	–	319
2022 Q2	$3K	Buy	+100	New	+$2.62K	﹤0.01%	240

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Hoey Investments's DNLI Position: Q3 2022 in Review

Hoey Investments sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 100 shares — an estimated $3K sold.

Hoey Investments first reported a position in DNLI in Q2 2022 and held it in 1 quarter. The position peaked at $3K in Q2 2022. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

Hoey Investments reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
Hoey Investments sold 100 Denali Therapeutics shares in Q3 2022, an estimated $3K.
Hoey Investments first reported a position in Denali Therapeutics in Q2 2022 and held it in 1 quarter.
Hoey Investments's Denali Therapeutics position peaked at $3K in Q2 2022.
200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on Hoey Investments's 13F filing for Q3 2022, filed 14 Nov 2022.